Indoleamine 2,3-dioxygenase vaccination

OncoImmunology

Volumn 4, Issue 1, 2015, Pages 983770-

  Andersen, Mads Hald ^a   Svane, Inge Marie ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

cancer vaccine; CD8; IDO; NSCLC; PD L1

Indexed keywords

CANCER VACCINE; HLA A2 ANTIGEN; INDOLEAMINE 2, 3 DIOXYGENASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; VACCINATION;

EID: 84938717671     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.983770     Document Type: Article

References (10)

1. A.J.Muller, G.C.Prendergast. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007; 7:31-40; PMID:17305476; dx.doi.org/10.2174/156800907780006896
2. C.Uyttenhove, L.Pilotte, I.Theate, V.Stroobant, D.Colau, N.Parmentier T.Boon, B.J.Van den Eynde. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-74; PMID:14502282; dx.doi.org/10.1038/nm934
3. R.B.Sorensen, S.R.Hadrup, I.M.Svane, M.C.Hjortso, P.thor Straten, M.H.Andersen. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 2011; 117:2200-10; PMID:21079151; dx.doi.org/10.1182/blood-2010-06-288498
4. T.Z.Iversen, L.Engell-Noerregaard, E.Ellebaek, R.Andersen, S.K.Larsen, J.Bjoern, C.Zeyher, C.Gouttefangeas, B.M.Thomsen, B.Holm Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 2014; 20:221-32; PMID:24218513; dx.doi.org/10.1158/1078-0432.CCR-13-1560
5. R.C.Harris, K.A.Chianese-Bullock, G.R.Petroni, J.T.Schaefer, L.B.Brill, K.R.Molhoek D.H.Deacon, J.W.Patterson, C.L.SlingluffJr. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. J Immunother 2012; 35:78-88; PMID:22130163; dx.doi.org/10.1097/CJI.0b013e31823731a4
6. Fishelevich R, Zhao Y, Tuchinda P, Liu H, Nakazono A, Tammaro A, et al. Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells. J Immunol 2011; 187:1664-1673; PMID: 21765012; dx.doi.org/10.4049/jimmunol.1100755
7. A.J.Davidoff, M.Tang, B.Seal, M.J.Edelman. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:2191-7; PMID:20351329; dx.doi.org/10.1200/JCO.2009.25.4052
8. Y.Nagata, T.Hanagiri, M.Mizukami, K.Kuroda, Y.Shigematsu, T.Baba, Y.Ichiki, M.Yasuda, T.So, M.Takenoyama, K.Sugio Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan. Lung Cancer 2009; 65:91-97; PMID:19054590; dx.doi.org/10.1016/j.lungcan.2008.10.012
9. M.H.Andersen. FOXP3-specific immunity. Oncoimmunology 2013; 2:e26247; PMID:24498544; dx.doi.org/10.4161/onci.26247
10. S.M.Ahmad, S.K.Larsen, I.M.Svane, M.H.Andersen. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia 2014; 28:236-38; PMID:24091833; dx.doi.org/10.1038/leu.2013.261